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Abstract	
The	management	 of	 high-risk	 prostate	 cancer	 has	 become	 increasingly	 sophisticated	with	
refinements	 in	 radical	 therapy	 and	 the	 inclusion	of	 adjuvant	 local	 and	 systemic	 therapies.		
Despite	this,	high-risk	prostate	cancer	continues	to	have	significant	treatment	failure	rates	
with	progression	to	metastasis,	castrate	resistance,	and	ultimately	disease-specific	death.	In	
an	effort	to	discuss	the	challenges	in	this	field,	the	UK	NCRI	Prostate	Cancer	Clinical	Studies	
Localised	Sub-Group	convened	a	multi-disciplinary	national	meeting	in	the	autumn	of	2014.	
The	 remit	 of	 the	 meeting	 was	 to	 debate	 and	 reach	 a	 consensus	 on	 the	 key	 clinical	 and	
research	challenges	in	high-risk	prostate	cancer	and	to	identify	themes	that	the	UK	would	be	
best	placed	to	pursue	to	help	improve	outcomes.	This	report	presents	the	outcome	of	those	
discussions	and	the	key	recommendations	for	future	research	in	this	highly	heterogeneous	
disease	entity.	
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Introduction	
Prostate	cancer	 is	the	commonest	male	malignancy	 in	the	western	world	with	41,736	new	
cases	reported	in	2011	for	the	UK	alone	(1).		In	men	with	new	diagnoses	the	proportion	of	
men	 presenting	with	High	 Risk	 Prostate	 Cancer	 (HR-PC)	 is	 rising	 year	 on	 year	 (2).	 Studies	
from	a	number	of	 centres	have	 shown	 that	primary	 radical	 therapy	 can	be	very	effective;	
however	men	with	 HR-PC	 have	 the	 highest	 incidence	 of	 disease	 relapse	 and	 progression.	
Evidence-based	practice	in	HR-PC	has	been	hampered	by	a	lack	of	appropriate	randomised	
controlled	 studies	 except	 in	 the	 field	 of	 external	 beam	 radiotherapy	 (EBRT).	 As	 a	 result,	
current	 clinical	 management	 is	 mainly	 driven	 by	 data	 from	 large	 case	 series	 and	
observational	 studies.	 To	 address	 this,	 the	 National	 Clinical	 Research	 Institute	 (NCRI)	
Prostate	Cancer	Clinical	Studies	Localised	Sub-group	held	a	1-day	multi-disciplinary	meeting	
on	 HR-PC	 on	 the	 17th	 November	 2014	 in	 London,	 UK.	 The	 remit	was	 to	 evaluate	 current	
clinical	pathways	 in	 the	management	of	patients	with	HR-PC	 in	 the	UK	and	to	 identify	key	
research	priorities	in	this	field.		
The	meeting	included	a	multi-disciplinary	group	of	healthcare	professionals	that	are	actively	
involved	in	managing	patients	or	researching	HR-PC	along	with	a	lay	expert	member	of	the	
public	(Table	1).		The	primary	objective	of	the	meeting	was	to	1)	discuss	the	current	clinical	
pathways	 (from	 definition	 to	management)	 of	 patients	with	 HR-PC	 and	 2)	 to	 identify	 key	
areas	that	required	further	research.	 	Prior	to	the	meeting,	topics	for	discussion	were	pre-
selected	 and	 specific	 members	 of	 the	 group	 were	 asked	 to	 review	 the	 current	 state	 of	
evidence	and	research	on	the	respective	topics	allocated	to	them.		The	findings	were	then	
presented	at	the	meeting	to	the	rest	of	group	followed	by	a	moderated	discussion	in	order	
to	reach	a	consensus	view.	 	The	top	priorities	 in	each	domain	are	 listed	here	 in	the	Tables	
relevant	 to	 each	 section.	 The	meeting	was	 chaired	 jointly	 by	 an	 epidemiologist	 (KM)	 and	
patient	representative	(DS).	
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Name	 Place	of	work	 Speciality	
Roberto	Alonzi	 London	 Oncology	
Mathias	Winkler	 London	 Urology	
Anne	Warren	 Cambridge	 Pathology	
John	Staffurth	 Cardiff	 Oncology	
Alison	Tree	 London	 Oncology	
Alan	Macneill	 Edinburgh	 Urology	
Rhona	McMenemin	 Newcastle	 Oncology	
Malcolm	Mason	 Cardiff	 Oncology	(CSG	Chair)	
Vincent	Khoo	 London	 Oncology	
Paul	Cathcart	 London	 Urology	
Nandita	de	Souza	 London	 Radiology	
Vincent	Gnanapragasam	 Cambridge	 Urology		
David	Smith	 	-		 Patient	advocate	(Chair)	
Kenneth	Muir	 Manchester	 Epidemiology	(Chair)	
P	Sooriakumaran	 Oxford	 Urology	
Robin	Weston	 Liverpool	 Urology	
James	Wylie	 Manchester	 Oncology	
Emma	Hall	 London	 Statistics	
Athene	Lane	 Bristol	 Clinical	Trials	
William	Cross	 Leeds	 Urology	
Isabel	Syndikus	 Clatterbridge	 Oncology	
Anthony	Koupparis	 Bristol	 Urology	
	
Table	1	–	Participants	and	designations	of	the	HR-PC	consensus	meeting	
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Current	perspectives	on	the	clinical	management	of	high-risk	prostate	cancer	
Definitions	of	high-risk	disease	
The	definition	of	HR-PC	is	contentious	and	varies	with	different	guidelines.		The	first	of	the	
risk	 stratification	 tools	 that	was	 developed	 for	 localised	 prostate	 cancer	was	 the	D’Amico	
classification.	 In	 this	 classification,	 high-risk	 patients	 are	 grouped	 as	 those	 with	 a	 PSA	
>20ng/ml,	Gleason	score	8-10	or	patients	with	clinical	T2c	and	above.	This	classification	 is	
the	basis	 for	 the	current	American	Urological	Association	 (AUA)	and	UK	National	 Institiute	
for	Clinical	Excellence	(NICE)	classifications.		The	European	Association	of	Urology	(EAU)	and	
the	National	Comprehensive	Cancer	Network	(NCCN)	guidelines	both	define	high-risk	cancer	
as	Gleason	score	8-10,	PSA	>20ng/ml	or	clinical	stage	T3a	(as	opposed	to	T2c	in	the	D’Amico	
classification).		The	UCSF-CAPRA	score	(University	of	California,	San	Francisco	–	Cancer	of	the	
Prostate	Risk	Assessment)	on	the	other	hand,	also	takes	into	consideration	the	percentage	
core	positivity	following	prostatic	biopsies	although	its	use	is	mainly	limited	parts	of	the	US.			
There	 is	 increasing	recognition	that	prognosis	can	differ	markedly	amongst	HR-PC	patients	
and	that	there	is	significant	heterogeneity	within	this	group.		Joniau	et	al	demonstrated	in	a	
multi-centre,	 retrospective	 study	 of	 1360	 patients	 with	 HR-PC	 treated	 by	 radical	
prostatectomy	 that	 three	 distinct	 groups	 of	 patients	 could	 be	 identified	 with	 differing	
survival	profiles	(3).		Lowest	risk	patients	were	those	who	had	a	single	high	risk	factor	with	a	
10-year	 prostate	 cancer	 survival	 (PCS)	 rate	 of	 88.3%.	 	 The	 intermediate	 prognosis	 group	
were	patients	with	a	PSA	>20ng/ml	and	stage	cT3-4	while	the	poorest	prognosis	sub-group	
had	all	three	high	risk	factors	(PCS	of	79.7%)	(3).			
The	 group	 noted	 that	 current	 risk	 stratification	 systems	 relied	 mainly	 on	 retrospective	
studies	with	outcomes	based	on	high	volume	academic	centres	with	particular	expertise	in	
the	management	of	HR-PC.	 	 In	 the	 study	by	 Joniau	et	al	 for	example,	as	all	patients	were	
managed	with	radical	prostatectomy,	 it	 is	conceivable	that	the	group	defined	as	the	 ‘high-
risk’	sub-group	may	in	fact	be	more	accurately	classified	as	intermediate	risk	and	may	have	
had	features	that	would	favour	the	clinicians	to	recommend	radical	surgery	(case-selection	
bias)	(3).		Furthermore,	as	high-volume	surgeons	were	performing	the	surgery,	the	positive	
margin	rates	were	particularly	 low	and	patients	therefore	had	a	better	prognosis	from	the	
outset.			
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Partly	 because	 of	 this	 intergroup	 heterogeneity,	 there	 has	 been	 intensive	 research	 into	
other	ways	to	better	stratify	patients,	not	only	for	HR-PC,	but	across	the	disease	spectrum.	
The	use	of	molecular	predictive	markers	such	as	the	cell	cycle	progression	panel	(CCP)	and	
the	Oncotype	Dx	 test	 have	 all	 entered	 commercial	 use	on	 this	 basis.	 The	 clinical	 role	 and	
cost-effectiveness	of	these	panels	in	current	clinical	management	remains	to	be	elucidated	
particularly	within	the	context	of	sub-optimal	clinical	risk	prediction	models.	
The	 clinical	 utility	 of	 nomograms	 was	 also	 discussed.	 It	 was	 generally	 agreed	 that	
nomograms	might	be	a	useful	way	of	presenting	a	non-biased,	objective	measure	of	risk	to	
patients	 diagnosed	with	 prostate	 cancer.	 However	most	UK	 oncologists	 and	 urologists	 do	
not	use	these	predictive	tools	as	the	majority	of	nomograms	are	based	on	historical	US	data	
that	is	very	different	from	the	UK	population.	Thus,	it	was	felt	that	there	was	an	urgent	need	
to	develop	nomograms	and	risk	models	based	on	UK	data.	
In	 summary,	 there	 is	 evidence	 to	 suggest	 that	 prognosis	 differs	 even	 in	 the	 context	 of	
patients	with	 HR-PC.	 	 Future	 studies	 should	 therefore	 concentrate	 on	 better	 defining	 the	
different	 sub-categories	 that	 may	 exist	 within	 a	 HR-PC	 classification.	 Any	 future	 risk	
prediction	 tools	 need	 to	 be	 developed	 based	 on	 contemporary	 UK	 data	 in	 order	 to	 be	
applicable	and	also	include	patients	from	across	the	spectrum	of	treatments.			
Current	treatment	pathways	and	outcomes	
The	 optimal	 treatment	 for	 patients	with	 HR-PC	 is	 currently	 unknown.	 	 Typically,	 high-risk	
patients	 are	 treated	 with	 EBRT	 with	 neo-adjuvant	 and	 adjuvant	 Androgen	 Deprivation	
Therapy	(ADT)	for	2-3	years.	There	is	evidence	of	improved	overall	survival	for	this	combined	
modality	approach	in	patients	with	locally	advanced	disease	from	two	randomised	trials	(4-
5).	 	 In	 the	NCIC	Clinical	 Trials	Group	PR.3/Medical	Research	Council	 PR07/Intergroup	T94-
0110	trial	patients	who	received	EBRT	and	ADT	had	a	74%	survival	at	7	years	compared	to	
66%	in	men	who	received	ADT	(4).		
In	 the	UK,	 the	majority	 of	 patients	 are	 treated	with	 EBRT	 to	 a	 dose	of	 74-78	Gy	 in	 37-39	
fractions.		This	typically	results	in	a	5-year	biochemical	relapse	free	survival	of	approximately	
75-81%	in	patients	with	localised	disease,	but	perhaps	as	low	as	57%	in	high-risk	patients	(6).		
There	 is	some	recognition,	that	HR-PC	may	behave	radio-biologically	 in	a	different	manner	
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compared	 to	 low	 risk	 prostate	 cancer.	 Dasu	 et	 al	 reported	 that	 in	 patients	with	 high-risk	
disease	74	Gy	did	not	achieve	adequate	control	of	the	tumour	with	a	total	radiation	dose	of	
>80Gy	 often	 being	 required	 (7).	 Another	 explanation	 for	 the	 poorer	 EBRT	 response	 could	
also	 be	 a	 higher	 tumour	 burden	 within	 the	 prostate	 in	 men	 with	 HR-PC.	 An	 interesting	
question	in	this	regard	is	whether	the	dose	distribution	of	EBRT	could	be	risk-adapted	and	in	
the	 UK,	 studies	 such	 as	 the	 recently	 completed	 DELINEATE	 trial	 could	 help	 answer	 this	
(ISRCTN:	04483921).	In	this	pilot	study	the	aim	was	to	test	the	value	of	increasing	radiation	
dosage	to	MRI-visible	tumours	within	the	prostate.		
Another	 potential	 method	 by	 which	 the	 effectiveness	 of	 EBRT	 could	 be	 improved	 is	 by	
combination	 with	 other	 agents	 that	 are	 designed	 to	 block	 androgen	 receptor	 signalling.		
Current	 trials	 for	 example	 are	 specifically	 looking	 at	 the	 HR-PC	 group	 and	 whether	 the	
combination	of	EBRT	with	agents	such	as	enzalutamide	can	result	in	a	survival	advantage	(8).		
It	 is	 currently	 unknown	 whether	 irradiating	 the	 prostate	 alone	 is	 sufficient	 in	 the	
management	of	patients	with	prostate	cancer,	or	whether	the	whole	pelvis	should	also	be	
irradiated.		Lepinoy	et	al	recently	reported	that	in	patients	who	had	biochemical	recurrence	
following	EBRT	(primary	or	salvage),	45%	of	nodal	relapses	were	observed	to	occur	outside	
the	standard	EBRT	field	(9).		The	study	authors	therefore	concluded	that	the	upper	field	limit	
of	pelvic	EBRT	should	be	extended	to	L2-L3	in	order	to	cover	95%	of	nodal	stations	that	are	
at	 risk	 of	 an	 occult	 relapse	 (9).	With	 the	 lack	 of	 level	 1	 evidence	 to	 support	 pelvic	 nodal	
irradiation	however,	it	is	unknown	whether	further	extending	the	field	to	include	para-aortic	
nodes	would	 result	 in	 any	 advantage	 for	 these	 patients.	 The	 additional	 toxicity	 is	 also	 of	
concern	 although	 the	 phase	 II	 PIVOTAL	 trial	 has	 shown	 low	 levels	 of	 toxicity	 with	 pelvic	
nodal	IMRT	in	this	setting	(10).	
The	group	identified	that	there	were	key	areas	in	current	management	of	HR-PC	with	EBRT	
that	require	further	investigation.	Firstly,	it	is	unknown	whether	further	escalating	the	dose	
in	 patients	with	 HR-PC	 can	 improve	 survival	 outcomes	 in	 patients	who	 are	 being	 treated	
with	 concurrent	 ADT.	 There	 is	 an	 increasing	 ability	 to	 do	 this	with	 precision	 using	 image-
guided	and	intensity	modulated	EBRT	approaches	to	avoid	toxicities	to	surrounding	normal	
tissues.	 Secondly,	 the	 molecular	 mechanism	 by	 which	 ADT	 and	 EBRT	 together	 improves	
survival	 outcome	 is	 also	 not	 well	 understood.	 The	 perceived	 notion	 is	 that	 ADT	 may	 be	
	 9	
having	 an	 effect	 on	 early	 micro-metastatic	 disease	 and	 hence	 result	 in	 better	 systemic	
control	and	survival	outcome	 in	 this	group	of	patients.	There	 is	however	no	evidence	that	
ADT	 as	 an	 adjunct	 treatment	 for	 radical	 prostatectomy	 confers	 a	 similar	 survival	 benefit	
though	 this	 question	 remains	 controversial	 (11).	 This	 suggests	 that	 there	 might	 be	 a	
mechanism	unique	to	EBRT.		Such	mechanisms	may	include	the	effect	of	ADT	in	permitting	
quiescent	androgen	receptor	negative	prostate	cancer	stem	cells	to	replicate	thus	allowing	
them	 to	 become	 susceptible	 to	 EBRT.	 There	 is	 also	 emerging	 data	 that	 the	 androgen	
receptor	 is	 a	 critical	 pathway	 in	 the	 regulation	 of	 DNA	 damage	 repair	 pathways	 (12-13).		
Here,	the	hypothesis	is	that	androgen	deprivation	results	in	the	suppression	of	the	androgen	
receptor,	which	in	turn	suppresses	DNA	repair	and	enhances	the	effect	of	EBRT.		
Historically,	radical	prostatectomy	was	a	treatment	modality	reserved	for	patients	with	low	
to	 intermediate	 risk	prostate	cancer.	 	 It	was	generally	 thought	 that	patients	with	high-risk	
disease	treated	with	radical	prostatectomy	developed	biochemical	recurrence	and	systemic	
progression	more	readily	compared	to	those	patients	who	were	treated	with	radical	EBRT	as	
the	primary	treatment	modality	(14).	Recently	however,	studies	have	challenged	this	notion	
and	radical	prostatectomy	has	slowly	become	an	established	alternative	to	patients	with	HR-
PC	 (15).	 A	 number	 of	 retrospective	 observational	 studies	 have	 suggested	 that	 radical	
prostatectomy	may	 confer	 improved	 survival	 outcomes	 compared	 to	 EBRT	 (16).	With	 the	
advancement	of	technology	(laparoscopic	and	more	recently,	robotic-assisted	surgery)	and	
improvements	in	morbidity	and	functional	outcomes,	the	uptake	of	radical	prostatectomy	in	
the	UK	has	increased	considerably	in	the	last	decade.	Increasingly,	radical	prostatectomy	is	
regarded	 by	 both	 urologists	 and	 oncologists	 as	 an	 important	 part	 of	 a	 multi-modality	
treatment	approach	in	the	management	of	HR-PC	(17-18).	From	the	outset,	these	patients	
are	 counselled	 that	 they	may	 require	 adjuvant	 treatment	with	 EBRT	and	possibly	ADT.	 	 It	
was	noted	however	 that	 there	 is	no	evidence	 to	 suggest	 the	 superiority	of	 this	 treatment	
modality	 over	 primary	 radiotherapy	 and	 this	 concept	 has	 entered	 mainstream	 practice	
without	 a	 strong	 evidence	 base.	 	 Thus,	 the	 group	 acknowledged	 this	 to	 be	 an	 on-going	
future	clinical	research	priority	and	there	was	a	general	feeling	that	the	UK	would	be	ideally	
suited	 to	 conduct	 a	 head-to-head	 trial	 on	 multi-modality	 treatment	 with	 surgery	 as	 the	
initial	intervention	versus	radical	EBRT	with	ADT	alone.	Until	then	the	group	recognised	that	
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the	current	selection	of	surgery	or	EBRT	as	the	primary	treatment	modality	should	be	judged	
on	an	individual	basis	and	centred	on	patient	and	practitioner	joint	decision-making	(19).		
Factors	in	HR-PC	treatment	selection	
There	are	a	number	of	issues	that	need	to	be	considered	in	selection	of	therapy	for	HR-PC.	
These	 include	 disease	 aggressiveness,	 life	 expectancy,	 co-morbidity,	 functional	 outcomes	
and	 complications	 of	 treatment	 as	 well	 as	 the	 consequences	 of	 failed	 primary	 therapy.	
Paramount	 is	 also	 the	 patient’s	 own	 choice	 of	 the	 best	 therapy	 for	 themselves	 based	 on	
considerations	of	quality	of	life	as	well	as	length	of	life	(19).		
	
Data	 from	 the	 literature	 in	 which	 the	 number	 of	 high-risk	 factors	 has	 been	 shown	 to	
influence	outcome	from	radical	prostatectomy	have	already	been	discussed.	It	is	however	as	
yet	 unknown	 if	 this	 is	 also	 the	 case	 for	 EBRT.	 Age	 and	 co-morbidity	 also	 have	 a	 major	
influence	 on	 the	 outcome	 of	 therapy.	 Competing	 risk	 analyses	 that	 have	 been	 published	
from	both	natural	history	(non-treatment)	studies	as	well	as	following	therapy	have	clearly	
shown	 that	 the	benefits	 from	 radical	 treatment	are	mainly	 seen	 in	 younger	men	with	 the	
fewest	co-morbidities	(20-21).	However,	this	will	need	regular	review	within	the	context	of	a	
much	 longer-living	 population	 in	 the	 western	 world	 and	 the	 improving	 general	 health	 of	
men.			
	
Functional	 and	 complication	 outcomes	 between	 EBRT	 and	 surgery	 have	 been	 keenly	
debated	over	the	years	and	there	is	a	significant	lack	of	comparable	data	from	studies	that	
have	used	 similar	 outcome	measures	 between	modalities.	 The	Prostate	Cancer	Outcomes	
Study	 has	 shed	 some	 light	 on	 this	 and	 it	 is	 clear	 that	 radical	 surgery	 and	 EBRT	 confer	
significant	detrimental	 effects	 to	urinary	 and	 sexual	 functions	 although	bowel	dysfunction	
seems	 to	be	 remarkably	 similar	between	 the	 two	groups	 (22).	 This	particular	 study	which	
prospectively	 followed	men	over	15	years	also	demonstrated	that	after	 intervention	there	
was	 a	 gradual	 decline	 in	 all	 domains	 over	 a	 period	 of	 time	which	most	 likely	 reflects	 the	
effect	of	age.	Between	 the	2	modalities	most	 studies	have	shown	that	 surgery	appears	 to	
have	 the	 greatest	 detrimental	 effect	 on	 urinary	 and	 sexual	 function.	 Conversely	
observational	work	by	Nam	et	al	from	Canadaian	registry	data	has	suggested	that	treatment	
by	 EBRT	 may	 have	 an	 increased	 risk	 of	 non-urinary	 and	 erectile	 complications	 requiring	
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hospital	 admissions	 including	 rectal	 or	 anal	 procedures,	 open	 surgical	 procedures	 and	
secondary	malignancies	(23).		
	
The	 group	 discussed	whether	 treatment	 selective	markers	 could	 be	 used	 as	 a	method	 of	
helping	 patients	 and	 clinicians	 choose	 the	 best	 first	 radical	 therapy	 option.	 Biomarker	
research	 in	 this	 area	 is	 very	 sparse	 and	 to	 date	 there	 are	 no	 studies	 which	 have	
demonstrated	 that	 any	 one	 biomarker	 can	 help	 stratify	 patients	 (24).	 There	 is	 however	
emerging	evidence	of	this	being	a	possibility.	An	example	is	the	BRCA2	mutation	(about	2%	
of	the	prostate	cancer	population)	whereby	carriers	of	the	mutation	are	known	to	have	poor	
outcomes	 from	 EBRT	 and	 potentially	 may	 do	 better	 from	 surgery	 instead	 (25).	 Another	
possible	 approach	 is	 to	 consider	 the	 toxicities	 from	 different	 treatments.	 In	 this	 context,	
studies	 are	 currently	 exploring	 how	 genomic	 predictors	 (e.g.	 single	 nucleotide	
polymorphisms)	 might	 identify	 men	 who	 are	 most	 susceptible	 to	 radiation	 damage	 to	
normal	tissue	and	hence	be	better	managed	by	non-EBRT	or	reduced	dose	therapy	methods	
(26).	 UK	 trials	 such	 as	 Radiogenomics:	 Assessment	 of	 Polymorphisms	 for	 Predicting	 the	
Effects	 of	 EBRT	 (RAPPER)	 and	 the	 linking	 radiation	 dose	 at	 the	 VOXel	 level	 with	 TOXicity	
(VOXTOX)	 are	 currently	 exploring	 this	 area	 of	 study	 (UKCRN	 Trials:	 1471	 and	 13716	
respectively).		
	
The	group	concluded	that	currently	 there	 is	no	 level	1	evidence	to	suggest	 the	benefits	of	
one	radical	treatment	option	over	another	and	very	 little	research	 in	stratified	approaches	
to	 therapy.	 In	 this	 context	 the	 discussion	 centred	 on	 the	 patients	 own	 choice	 of	 therapy.	
They	 recognise	 that	 a	 patient’s	 choice	 is	 very	 individual	 and	 can	 rely	 on	 their	 own	
experiences,	 the	 influence	 of	 family	 and	 other	 co-existing	 conditions	 (e.g.	 urinary	 tract	
symptoms)	and	also	 to	a	 large	extent	on	who	they	see	 in	 the	clinics	and	what	counselling	
they	 receive.	 	 Most	 attendees	 agreed	 that	 for	 the	 younger	 or	 fitter	 men	 with	 high-risk	
disease,	 surgery	may	be	 the	best	 initial	 option	but	 again	 this	 is	 down	 to	 a	 very	 individual	
decision	of	the	consultation	between	the	patient	and	the	surgeon.	Quality	of	life	becomes	a	
key	factor	here	and	going	forward	studies	in	both	EBRT	and	surgery	have	to	consider	using	
standardised	methods	of	reporting.		The	group	agreed	that	patients	still	very	much	rely	on	
clinicians	 for	 guidance	 and	 that	 this	 is	 unlikely	 to	 change	 in	 the	 near	 future.	 Discussions	
about	salvage	options,	should	primary	therapy	fail,	is	also	a	difficult	area	to	approach	when	
	 12	
a	patient	is	considering	first	treatment.	However,	considering	the	significant	morbidity	from	
salvage	treatments,	it	probably	needs	to	be	brought	further	up	the	agenda	when	discussing	
the	treatment	choices.		
	
Despite	the	lack	of	concrete	evidence,	the	group	did	feel	that	there	might	be	some	value	in	
considering	 constructing	 a	 treatment	 choice	 algorithm.	 This	 might	 include	 the	 factors	
discussed	within	this	topic	area	to	help	the	clinician	and	patient	make	the	most	appropriate	
decision	 for	 radical	 treatment	 to	manage	HR-PC.	 All	meeting	 participants	 recognised	 that	
randomised	 controlled	 trials	 in	 this	 area	 are	 going	 to	 be	 very	 difficult	 to	 achieve	 to	 help	
inform	 such	 an	 algorithm.	 One	 alternative	 option	 however	 is	 to	 consider	 collecting	 data	
prospectively	in	registration	studies	and	to	include	standardised	composite	oncological	and	
quality	 of	 life	measures.	 In	 this	 regard	work	 initiated	 by	 the	 International	 Consortium	 on	
Health	 Outcomes	 is	 very	 welcome	 (27).	 Table	 2	 summarises	 the	 key	 clinical	 questions	
highlighted	by	the	group.	
	
Table	2	-	Summary	of	the	key	clinical	uncertainties	in	HR-PC	
	
1.					Unmet	need	for	better	tools	to	risk	stratify	HR-PC	patients	to	identify	optimal	primary	
treatment	combinations	and	those	who	may	need	early	therapy	escalation.	
2.							Uncertainty	on	the	best	primary	treatment	combination	for	HR-PC	and	the	on-going	
need	to	undertake	a	randomised	trial	in	this	group.		
3.							In	the	lack	of	prospective	randomised	data,	how	do	we	make	equitable	comparisons	of	
the	impact	of	different	radical	treatments	on	functional	outcome	and	quality	of	life	
measures?		
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Research	priorities	in	high-risk	prostate	cancer	
Research	in	radiotherapy		
Over	 the	 past	 decade	 development	 of	 new	 EBRT	 techniques	 such	 as	 intensity-modulated	
radiation	therapy,	3-D	conformational	radiation	therapy,	high	and	low	dose	brachytherapy,	
image	guided	radiation	therapy	and	proton	beam	therapy	have	made	the	delivery	of	higher	
doses	of	radiation	possible	with	acceptable	associated	morbidity.	Further	evaluation	of	the	
role	 of	 these	 external	 techniques	 as	 well	 as	 high	 dose	 rate	 (HDR)	 brachytherapy	 in	 the	
management	 of	 HR-PC	was	 identified	 as	 a	 key	 research	 priority.	 Coupled	with	 this	 is	 the	
significant	current	research	interest	in	the	optimal	dose	fractionation	regime	and	timing	as	
well	as	how	this	is	best	combined	with	systematic	therapy.	
The	 UK	 has	 been	 an	 international	 lead	 for	 many	 recent	 innovations	 in	 technical	
radiotherapy.	An	example	of	this	is	the	planned	HEXPROP	study	which	will	be	a	multi-armed	
comparison	 of	 EBRT	 dose	 and	 pelvic	 node	 radiation.	 More	 recently,	 the	 radiotherapy	
community	 has	 been	 considering	 the	 role	 of	 EBRT	 in	 men	 with	 node	 positive	 and	 oligo-
metastatic	 disease	 though	 studies	 in	 this	 area	 are	 at	 an	 early	 stage.	 The	 Dutch	 HORRAD	
study	 (Trial	 register.nl	 NTR271),	 which	 randomised	 men	 with	 skeletal	 only	 metastatic	
disease	to	ADT	or	ADT	plus	local	EBRT	is	due	to	report	in	2015	and	the	results	will	no	doubt	
fuel	further	research	interest	on	this	topic.	In	the	UK	the	STAMPEDE	trial	has	already	added	
a	prostate	local	EBRT	arm	to	men	with	metastatic	disease	(ClinicalTrials.gov	NCT00268476).	
Other	 studies	 such	 as	 the	 recently	 funded	 CORE	 study	 	 (Conventional	 care	 versus	
radioablation	 for	 extracranial	 metastases)	 are	 exploring	 the	 benefits	 of	 targeted	 EBRT	 to	
metastatic	sites	in	men	who	have	progressed	despite	primary	androgen	deprivation	therapy.	
Radio-sensitisation	 using	 molecular	 targeted	 drugs	 prior	 to	 EBRT	 was	 identified	 as	 a	
potential	 way	 of	 further	 improving	 oncological	 responses.	 Radio-sensitising	 drugs	 which	
target	 apoptotic	 and	DNA	damage	 response	pathways	 are	due	 to	be	assessed	alone	or	 in	
combination	 in	 future	 trials.	 Tumour	 hypoxia	 is	 known	 to	 affect	 EBRT	 effectiveness	 and	
there	 are	 hypoxia	 modification	 studies;	 e.g.	 PROCON:	 A	 trial	 of	 PROstate	 EBRT	 in	
CONjunction	with	 carbogen	 and	nicotinamide	 (ISRCT:	N08912168)	 being	 conducted	 in	 the	
UK	to	determine	if	reversal	of	hypoxia	might	increase	the	efficacy	of	EBRT.	Radiotherapy	has	
also	been	 suggested	 to	 increase	 the	efficacy	of	 immunotherapy	 in	animal	models	 (28).	 To	
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date	 however	 human	 trials	 in	 the	 castrate	 refractory	 metastatic	 setting	 combining	 bone	
directed	radiotherapy	and	immunotherapy	have	not	so	far	shown	clinical	benefit	(29).		
Non-invasive	 imaging	 of	 the	 in	 situ	 prostate	 to	monitor	 treatment	 response	 such	 as	with	
Magnetic	Resonance	(MR)	or	Positron	Emission	Tomography	(PET)	was	also	discussed	with	
particular	 emphasis	 on	 identification	 of	 treatment	 failure	 before	 biochemical	 detected	
relapse.	 In	 this	context	 the	use	of	 imaging	during	 treatment	with	a	view	to	modulating	or	
escalating	doses	would	be	of	particular	interest.	The	role	and	place	of	MR	targeted	biopsies	
and	their	 timing	 in	relation	to	EBRT	to	 identify	suspected	recurrence	remains	unclear.	The	
use	of	such	biopsy	data	may	be	 informative	 in	confirming	recurrence	and	deciding	 further	
treatment	but	is	limited	by	post	treatment	radiation	atypia	that	can	make	the	diagnosis	and	
Gleason	 grading	 of	 recurrent	 tumours	 very	 difficult	 (30).	 The	 group	 also	 discussed	 the	
evidence	 for	 the	 use	 of	 tissue	 biomarkers	 as	 an	 alternative	 to	 guide	 salvage	 treatment	
choices	and	better	predict	 treatment	 response.	Here	 the	 significant	paucity	of	 research	 in	
the	 field	was	acknowledged	as	a	major	 limitation.	 	Table	3	summarises	 the	key	consensus	
radiotherapy	research	questions.	
	
Table	3		-	Research	priorities	in	radiotherapy			
1.	 What	 is	 the	 best	 radiotherapy	 fractionation	 regimes	 and	 combinations	 with							
optimised	dose	delivery	for	the	treatment	of	HR-PC?	
2.	 Does	 pelvic	 nodal	 and	 prostate	 ERBT	 have	 better	 oncological	 and	 functional	
outcomes	compared	to	prostate-only	ERBT?			
3.	 Can	 radio-sensitising	 drugs	 and/or	 hypoxia	 modification	 improve	 oncological								
responses	to	current	radiotherapy	regimes	while	reducing	toxicity?		
4.	 Can	tumour	molecular	characteristics	or	functional	imaging	characteristics	be	used	to	
help	guide	dose	delivery/escalation	and	predict	therapeutic	response?	
5.	 What	is	the	role	of	interim	or	post-radical	radiotherapy	functional	imaging	and	image	
targeted	biopsies	in	predicting	therapy	response	and	disease	recurrence?			
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Research	in	surgery	
There	has	been	a	sea	change	in	the	role	of	surgical	management	of	HR-PC.	Robotic-assisted	
laparoscopic	 prostatectomy	 (RALP)	 has	 now	 become	 the	 most	 common	 operation	 for	
localised	prostate	cancer	in	the	United	States	and	is	becoming	so	in	the	UK	as	well.	It	is	also	
emerging	 as	 an	 option	 in	 the	 management	 of	 locally	 advanced	 and	 localised	 high-risk	
disease.	 This	 change	 in	 practice	 has	 happened	 despite	 the	 ongoing	 uncertainty	 around	
which	 available	 methods;	 open,	 laparoscopic	 or	 RALP	 is	 the	 most	 effective	 and	 cost-
effective.	 Reviews	 of	 large	 observational	 studies	 have	 reported	 that	 RALP	 is	 at	 least	
comparable	 in	 efficacy	 to	 open	 prostatectomy	 with	 the	 majority	 of	 studies	 reporting	
favourable	 functional	 and	 oncological	 outcomes	 (31-33).	 However,	 these	 types	 of	 studies	
are	inherently	flawed	as	they	are	unable	to	control	for	variations	in	patient	factors,	surgical	
experience	 and	 caseloads,	 all	 of	 which	 can	 have	 a	 significant	 impact	 on	 the	 reported	
outcomes.	The	group	discussed	the	challenges	in	carrying	out	a	randomised	controlled	trial	
and	 questioned	 what	 other	 types	 of	 studies	 would	 be	 a	 reasonable	 alternative.	 The	 UK	
LOPERA	trial	(Laparoscopic,	Open	and	Robot-assisted	prostatectomy	as	treatment	for	organ-
confined	 prostate	 cancer	 ISRCTN:	 59410552)	 for	 instance	 comparing	 different	 types	 of	
radical	prostatectomy	failed	to	recruit	sufficient	patients.	Large	multi-centred	collaborations	
with	prospective	and	accurate	databases	were	deemed	a	potential	and	acceptable	way	of	
assessing	 these	 techniques.	 However,	 the	 group	 recognised	 that	 the	 current	 lack	 of	
standardised	 reporting	 between	 centres	 on	 oncological	 and	 functional	 outcomes	 makes	
direct	comparisons	challenging.			
The	 Royal	 College	 of	 Surgeons	 surgical	 trials	 initiative	 set	 up	 five	 surgical	 trial	 units	 (STU)	
across	 England	 to	 substantially	 increase	 surgical	 research	 capacity.	 The	 STUs	 aim	 to	 help	
support	 researchers	 to	 produce	 high-quality	 research	 that	 can	 benefit	 patients	 through	
improved	 clinical	 outcomes,	 better	 standards	 of	 care	 and	 a	 reduction	 in	 the	 regional	
variations	in	care.	The	units	however	have	reported	on-going	problems	with	gaining	funding,	
over-regulation	and	delays	 in	gaining	ethical	approval.	 	These	UK-wide	challenges	must	be	
addressed	in	order	to	ensure	surgical	 innovation	is	 implemented	promptly	and	safely.	 	The	
group	 also	 felt	 that	 any	 future	 surgical	 research	 should	 account	 for	 surgeon/centre	
experience	 as	 this	 heterogeneity	 has	 a	 strong	 influence	on	 reported	outcomes.	 	With	 the	
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advent	of	high	volume	centres	the	group	felt	running	large	randomised	trials	may	be	easier	
with	the	use	of	more	standardised	technical	approaches.		
The	 role	 of	 surgery	 in	 localised	 and	 locally	 advanced	HR-PC	 disease	was	 identified	 as	 key	
priority	areas	for	future	research.		A	higher	proportion	of	men	are	having	surgery	as	part	of	a	
first	step	in	the	multi-modal	management	of	their	disease.	In	some	patients	surgery	is	a	one-
step	 modality	 with	 excellent	 oncological	 prognosis	 however	 most	 men	 will	 need	 a	
multimodal	 approach.	 A	 key	 research	 area	 is	 in	 defining	 clinical	 or	 biological	 markers	 to	
select	 the	most	 appropriate	HR-PC	 candidates	 for	 surgery	with	 the	highest	 likelihood	of	 a	
good	outcome.	In	addition	this	may	also	help	determine	the	appropriate	sequencing,	timing	
and	intensity	of	multimodal	therapies.	Most	recently	surgery	has	also	been	proposed	as	an	
option	 for	 local	 treatment	 in	 men	 with	 olio-metastatic	 disease	 with	 observational	 data	
suggesting	 better	 biochemical	 and	 survival	 outcomes	 compared	 to	 palliative	 treatment	
alone	 (34-35).	 The	 evidence	 to	 date	 however	 is	 very	 limited	 and	mainly	 in	 small	 selected	
cohorts.	The	comparative	role	of	EBRT	or	surgery	 in	 local	therapy	for	men	with	metastatic	
disease	is	also	unknown	and	needs	further	research.	Table	4	summarises	the	key	consensus	
surgery	research	questions.	
	
Table	4	-	Research	priorities	in	surgery	
1.	 How	 can	we	better	 share	 learning	 experiences	 and	 adopt	 techniques	 from	 centres	
reporting	superior	surgical	oncological	and	functional	outcomes?			
2.	 How	do	we	select	the	best	patients	for	surgical	management	of	HR-PC	using	clinical,	
imaging	or	molecular	markers?	
3.	 What	 is	 the	 role	 of	 local	 therapy	 in	 the	management	 of	 oligo-metastatic	 disease?	
Should	this	be	treated	with	surgery	or	radiotherapy	or	a	combination	of	both?	
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Multi	modal	therapy		
There	was	a	broad	consensus	that	men	with	HR-PC	benefited	most	from	a	multi-disciplinary	
and	 multimodal	 approach	 to	 therapy.	 This	 included	 the	 optimal	 local	 therapy	 to	 the	
prostate,	 the	best	modality	 to	 treat	 lymph	nodes	and	the	role	and	timing	of	neo-adjuvant	
and	adjuvant	therapy.	ERBT	with	 long-term	ADT	has	 long	been	considered	the	standard	of	
care	 for	 HR-PC	 over	 other	 modalities.	 There	 still	 remains	 major	 controversy	 about	 the	
appropriate	duration	of	ADT.	The	majority	of	patients	now	have	ADT	started	prior	to	ERBT	
but	it	is	unclear	how	long	the	treatment	duration	should	be	and	how	this	would	differ	in	the	
context	 of	 different	 dose	 regimes	 and	 fractionation.	 The	 group	 also	 discussed	 the	
uncertainties	around	the	appropriate	technique	and	dose	of	EBRT	and	the	role	of	prostate-
only	versus	whole	pelvic	 irradiation.	 In	this	context	similar	uncertainties	exist	with	regards	
the	role	of	extended	lymph	node	dissections	in	surgery.	While	it	is	accepted	that	extended	
lymph	node	dissection	may	 improve	biochemical	 relapse	 rates	and	 certainly	provide	good	
staging	 information,	 it	has	not	yet	been	consistently	 shown	 to	 improve	 survival	and	 there	
are	 no	 randomised	 trials	 exploring	 this	 issue	 (36-37).	 Furthermore,	 the	 place	 and	 relative	
benefit	 of	 extended	 lymph	 node	 dissections	 within	 the	 context	 of	 contemporary	 post	
surgical	 adjuvant	 therapy	 is	 unknown.	 The	 group	 noted	 that	 in	 this	 context	 there	was	 an	
opportunity	 to	 explore	 complementary	 roles	 for	 different	modalities	 for	 treatment	 of	 the	
prostate	and	lymph	nodes	within	a	trial	setting.	
	
With	 the	emerging	possibility	of	accurate	molecular	 characterisation	of	 tumours	at	biopsy	
the	group	discussed	how	this	could	be	exploited	to	guide	selection	and	use	of	neo-adjuvant	
or	adjuvant	therapy.	There	was	particular	interest	in	the	possibility	of	prospective	trials	that	
might	 randomise	patients	 to	specific	 treatments	based	on	an	 individualised	understanding	
of	 molecular	 perturbations.	 Here	 options	 for	 targeted	 novel	 neo-adjuvant	 and	 adjuvant	
combinations	 alongside	 standard	 radical	 therapies	 should	be	 explored.	 Indeed	 these	have	
already	begun	with	current	studies	on	the	NCRI	CSG	portfolio	incorporating	novel	drugs	and	
surgery	 (e.g.	 CANCAP02,	NCT:02064608).	 The	 critical	 issue	 remains	 as	 to	how	 to	 translate	
the	use	of	molecular	profiling	into	real	time	clinical	practice	if	efficacy	is	shown	in	such	trials.	
In	the	context	of	new	agent	trials,	and	with	survival	outcomes	taking	a	long	time	to	accrue,	
there	is	a	clear	need	to	develop	and	validated	intermediate	and/or	surrogate	endpoints.	The	
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evidence	for	using	drugs	developed	 in	the	castrate	refractory	setting	and	trialled	 in	earlier	
stage	disease	was	also	debated.	The	group	noted	the	historical	failure	of	these	approaches	
to	provide	complete	responses	or	to	improve	survival	outcomes.	Of	note	these	studies	have	
been	mainly	in	the	surgical	setting	and	there	is	very	little	research	of	efficacy	in	EBRT	treated	
men.	 One	 example	 of	 this	 is	 the	 use	 of	 neo-adjuvant	 docetaxel	 chemotherapy	 prior	 to	
radical	 prostatectomy	 that	 to	date	has	not	 as	 yet	 shown	 survival	 benefit	 (38-40).	 Taxanes	
however	are	known	to	be	radio	sensitizers	 in	the	treatment	of	head	and	neck	cancers	and	
may	well	have	therapeutic	benefit	in	EBRT	based	treatment	of	HR-PC	(41).		
The	group	also	discussed	the	variety	of	different	oncological	and	functional	outcomes	used	
as	 endpoints	 in	 trials	making	 studies	 harder	 to	 compare	 and	 draw	 firm	 conclusions.	 	 The	
group	urged	that	future	research	should	try	and	use	standardised	functional	outcomes	and	
also	 consider	 using	 oncological	 outcomes	 more	 suited	 to	 non-metastatic	 disease	 e.g.	
freedom	from	the	need	for	ADT	or	residual	disease	on	MRI	after	EBRT.	Table	5	summarises	
the	key	consensus	multimodal	research	questions.	
	
Table	5	-	Research	priorities	in	multimodal	therapy			
1.	 What	 is	 the	appropriate	 timing,	optimal	duration	and	 type	of	 concurrent	androgen	
deprivation	therapy	in	EBRT	treated	HR-PC?		
2.	 What	 is	 the	optimal	management	of	 lymph	nodes	 in	HR-PC?	Do	patients	do	better	
with	surgical	excision	of	lymph	nodes	or	from	irradiation	of	lymph	nodes	+	ADT?	Can	
the	UK	 lead	 a	 randomised	 trial	 of	 lymph-node	 dissection	 versus	 lymph	 node	 EBRT	
following	radical	prostatectomy?		
3.	 How	can	we	exploit	 the	unique	molecular	 characteristics	of	 tumours	 to	help	 guide	
primary	 patient	 therapy	 and	 selection	 of	 multimodal	 therapy	 and	 use	 of	 neo-
adjuvant	or	adjuvant	drugs	in	conjunction	with	radical	therapy?	
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Salvage	therapy		
Men	with	HR-PC	have	 the	highest	 risk	of	 disease	 relapse	 after	 primary	 radical	 therapy.	 In	
post-surgical	 patients,	 salvage	 EBRT	with	 or	without	 ADT	 is	 the	mainstay	 of	management	
though	there	 remains	uncertainty	on	 the	optimal	duration,	dosage	and	timing	of	adjuvant	
treatment.	 These	 issues	have	been	partly	 addressed	by	 recent	 randomised	 adjuvant	 trials	
and	will	be	further	informed	by	the	current	UK	RADICALS	study	(Randomised	Controlled	Trial	
of	Radiology	and	Androgen	deprivation	in	combination	after	local	surgery)	(42-45).		
The	 issue	 is	 much	 more	 complex	 in	 radio-recurrent	 prostate	 cancer	 with	 a	 multitude	 of	
salvage	options	including	radical	prostatectomy,	brachytherapy,	cryotherapy,	high-intensity	
focused	ultrasound	and	other	new	emerging	ablative	technologies.	To	date	the	established	
modalities	appear	to	offer	similar	rates	of	cure	but	also	significantly	high	rates	of	functional	
morbidity	 and	 toxicity.	 There	 have	 been	 no	 randomised	 trials	 in	 this	 area	 and	 these	 are	
difficult	 to	 undertake	 as	 demonstrated	 by	 the	 failed	 CROP	 trial	 (deferred	 androgen	
deprivation	 therapy	 +/-	 upfront	 CRyOtherapy	 in	 men	 with	 localised	 radiation	 recurrent	
prostate	 cancer)	 (46).	Nevertheless,	 local	 salvage	 therapy	has	 the	potential	 to	be	 curative	
and	disease	control	has	been	reported	in	a	substantial	number	of	selected	patients.		Further	
research	 is	 required	 to	 determine	which	 patients	 should	 be	 offered	 local	 salvage	 therapy	
and	whether	or	not	the	therapeutic	advantage	is	enough	to	justify	the	associated	treatment-
related	morbidity.		
The	group	agreed	 that	 there	was	no	 level	1	evidence	available	 to	help	guide	clinician	and	
patient	decision	making	and	the	current	literature	is	lacking	on	good	quality	data	regarding	
treatment-associated	morbidity.	 Indeed	 it	 is	 currently	unknown	how	many	men	 in	 the	UK	
with	 radio-recurrent	 disease	 are	 offered	 and	 received	 salvage	 therapy.	 A	 further	
complication	 is	 the	diversity	of	oncological	outcome	measures	used	with	different	 salvage	
modalities.	 The	 timing	 and	 duration	 of	 adjuvant	 ADT	 with	 salvage	 therapy	 is	 also	 a	 key	
question	that	needs	to	be	answered.	The	group	agreed	that	a	UK	prospective	database	for	
all	men	who	received	salvage	therapy	should	be	developed	and	established.	This	may	be	the	
only	 viable	 alternative	 to	 a	 randomised	 controlled	 trial	 though	 the	 group	 recognised	 that	
other	 options,	 including	 cohort	 design	 trials,	 were	 also	 being	 considered	 (47).	 Table	 6	
summarises	the	key	consensus	salvage	therapy	research	questions.	
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Table	6	-	Research	priorities	in	salvage	therapy			
1.	 How	 do	 we	 best	 identify	 men	 who	 would	 benefit	 most	 from	 salvage	 therapy	
following	primary	radical	surgery	or	radiotherapy?		
2.					In	the	context	of	radio-recurrent	disease	how	can	the	best	salvage	option	be	identified?		
3.								If	a	randomised	trial	is	not	feasible,	can	a	national	prospective	database	of	men	who	
have	 received	 salvage	 treatment	 for	 radio-recurrent	 disease	 be	 set	 up	 using	
standardised	outcome	measures	for	oncological,	functional	and	toxicity	outcomes?			
	
Summary	
Compared	to	all	solid	cancers,	prostate	cancer	continues	to	have	some	of	the	best	survival	
outcomes	even	when	classified	as	high-risk	at	diagnosis.	The	group	recognised	this	and	the	
fact	 that	 outcomes	 in	 the	 UK	 from	men	 treated	 radically	 are	 comparable	 to	 those	 from	
international	series	(48-49).	However	men	with	HR-PC	continue	to	be	at	the	highest	risk	of	
treatment	failure	and	disease	progression.	The	group	therefore	agreed	that	a	critical	priority	
was	to	further	improve	curative	outcome	for	this	group	of	men.	Alongside	this	was	a	need	to	
reduce	the	toxicity	of	therapy	and	move	to	a	more	individual	method	of	selecting	treatment	
for	patients.		
	
The	 group	 recognised	 that	 the	 UK	 was	 well	 placed	 to	 undertake	 balanced	 and	 equitable	
research	 in	 HR-PC	 and	 that	 this	 was	 best	 achieved	 using	 a	 multi-disciplinary	 approach	
involving	 surgeons,	 oncologists,	 pathologists,	 radiologists	 and	 other	 allied	 medical	
specialities.	 Indeed	 the	 UK	 already	 has	 nationally	 endorsed	 standards	 for	 individual	 case	
discussions	within	multi-disciplinary	 teams.	 Furthermore	 there	 is	 generally	 good	 equity	 of	
treatment	options	available	to	patients	across	the	UK.	Despite	this,	 randomised	controlled	
trials	in	all	but	EBRT	studies	have	been	difficult	to	achieve,	not	least,	because	of	patient	and	
clinician	bias.	In	this	context	robust	prospective	recording	of	data	in	registration	studies	may	
well	be	able	to	deliver	valuable	outcomes	particularly	 if	 this	 included	standardised	toxicity	
and	quality	of	life	outcome	measures.	
	
HR-PC	was	recognised	to	be	a	heterogeneous	entity	and	there	is	a	need	for	focused	work	on	
sub-classifying	men	with	 high-risk	 disease	 to	 identify	 those	who	will	 and	will	 not	 do	well	
from	current	therapies.		At	the	moment,	the	inclusion	of	all	men	with	high-risk	disease	into	a	
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single	 group	 is	 untenable	 for	 future	 research	 and	 to	 achieve	 improvements	 in	 individual	
clinical	outcomes.		Thus	better	risk	models	need	to	be	defined	and	importantly	use	cohorts	
comparable	 to	 the	 UK	 population	 of	 patients.	 The	 integration	 of	 molecular	 and	 imaging	
biomarkers	into	such	optimised	models	may	further	help	to	refine	new	risk	models	and	help	
clinicians	and	patients	in	therapy	selection	and	decisions	about	treatment	escalation.	
	
A	 critical	 issue	 for	 both	 primary	 surgery	 and	 EBRT	 is	 how	 to	 deal	 with	 lymph	 node	
involvement	as	this	area	lacks	good	evidence-based	clinical	guidelines.	New	research	in	this	
field	may	well	need	to	avoid	the	traditional	separations	of	surgery	and	EBRT.	One	consistent	
research	 theme	 was	 whether	 surgery	 or	 EBRT	 (potentially	 including	 ADT)	 was	 the	 better	
treatment	 for	 suspected	 or	 detected	 lymph	 node	 disease	 and	 there	 is	 space	 here	 for	 a	
combined	effort	from	a	multi-disciplinary	research	team.	In	the	same	vein,	neo-adjuvant	and	
adjuvant	therapy	is	clearly	an	important	research	theme	and	the	group	endorsed	the	critical	
need	for	innovative	multi-disciplinary	trials.		
	
The	 debate	 on	 primary	 radical	 therapy	 in	men	with	 oligo-metastatic	 disease	 is	 becoming	
more	prominent	and	it	remains	unclear	what	the	role	of	radical	therapy	might	be.		A	crucial	
issue	however	is	to	ensure	that	any	radical	therapy	does	not	adversely	impair	quality	of	life	
given	the	fact	that	there	is	already	disseminated	disease	and	life	expectancy	will	be	reduced.		
In	this	context	quality	of	life	should	as	important	an	outcome	measure	of	any	study	in	this	
field	in	tandem	with	survival	outcomes.		
	
Finally,	 it	was	 recognised	 that	going	 forward	 it	 is	 the	 integration	of	molecular	 information	
derived	 at	 the	 beginning,	 during	 and	 after	 treatment	 that	 is	 going	 to	 define	 the	 next	
generation	 of	 smart	 treatments	 and	 improvements	 in	 outcome.	 	 This	 theme	 is	 being	
explored	but	perhaps	but	not	as	rapidly	as	necessary	and	the	group	felt	that	this	would	be	
an	area	that	would	be	ripe	for	investment	into	research	and	development.			
	
In	 conclusion	 it	 is	hoped	 that	 the	discussions	and	consensus	 from	this	meeting	 report	will	
help	 the	 UK	 Prostate	 Cancer	 Research	 Community	 to	 focus	 their	 research	 in	 HR-PC	 and	
provide	 direction	 for	 charitable	 funders.	 The	 key	 thematic	 areas	 to	 emerge	 as	 clinical	
uncertainties	and	research	priorities	have	been	listed	in	the	tables.	It	 is	very	likely	that	the	
	 22	
next	5-10	years	will	bring	important	changes	for	the	better	in	terms	of	HR-PC	outcomes	and	
allow	clinicians	to	provide	their	patients	with	the	holy	grail	of	individualised	optimal	therapy	
choice	with	the	most	durable	chance	of	cure	and	minimal	morbidity.	
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